Study S000265

A Multicentre, Randomised, Double-blind, Placebo-controlled 52-week, Phase IIIb Trial to Evaluate the Efficacy and Safety of Survodutide in Peri- and Post-menopausal Women With Overweight or Obesity (SYNCHRONIZE®-HERA)

ClinicalTrials.gov record

Registration

Registration: NCT07850050
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 600
Start: 2026-10-31
Primary completion: 2028-07-26
Lead sponsor: Boehringer Ingelheim
Conditions: Obesity
Interventions: COMBINATION_PRODUCT:Survodutide; COMBINATION_PRODUCT:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:U1111-1338-2684; REGISTRY:2026-527092-29-00

Registered primary outcomes

Percentage change in body weight from baseline to Week 52 [At baseline and Week 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.